Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcos de Lima

Showing results (131-140 of 321) with videos related to

Pageof 33
Sort By:
Cancer|April 15, 2005
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experienceHagop Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
American Journal of Hematology|November 6, 2018
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American expertsNicholas J Short, Elias Jabbour, Maher Albitar, et al.
Transfusion|May 18, 2011
Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantationChitra Hosing, Veronica Smith, Beverly Rhodes, et al.
Cancer Discovery|May 13, 2022
Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin LymphomaZachary Jackson, Changjin Hong, Robert Schauner, et al.
Blood|October 7, 2010
Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapyFarhad Ravandi, Jorge Cortes, Stefan Faderl, et al.
Blood|January 17, 2004
Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type mattersMaha El-Zimaity, Rima Saliba, Kawah Chan, et al.
Leukemia & Lymphoma|February 2, 2011
Allogeneic hematopoietic stem cell transplant after intravenous busulfan and fludarabine conditioningFábio R Kerbauy, Morgani Rodrigues, Fábio Pires de Souza Santos, et al.
American Journal of Hematology|June 11, 2013
Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilizationVeronica R Smith, Uday Popat, Stefan Ciurea, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2013
Hematopoietic cell transplantation-specific comorbidity index predicts inpatient mortality and survival in patients who received allogeneic transplantation admitted to the intensive care unitUlas D Bayraktar, Elizabeth J Shpall, Ping Liu, et al.
Cancer|July 31, 2010
Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding studyMarcos de Lima, Sergio Giralt, Peter F Thall, et al.
Pageof 33

Showing results (131-140 of 321) with videos related to

Sort By:
Pageof 33
Cancer|April 15, 2005
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experienceHagop Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
American Journal of Hematology|November 6, 2018
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American expertsNicholas J Short, Elias Jabbour, Maher Albitar, et al.
Transfusion|May 18, 2011
Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantationChitra Hosing, Veronica Smith, Beverly Rhodes, et al.
Cancer Discovery|May 13, 2022
Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin LymphomaZachary Jackson, Changjin Hong, Robert Schauner, et al.
Blood|October 7, 2010
Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapyFarhad Ravandi, Jorge Cortes, Stefan Faderl, et al.
Blood|January 17, 2004
Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type mattersMaha El-Zimaity, Rima Saliba, Kawah Chan, et al.
Leukemia & Lymphoma|February 2, 2011
Allogeneic hematopoietic stem cell transplant after intravenous busulfan and fludarabine conditioningFábio R Kerbauy, Morgani Rodrigues, Fábio Pires de Souza Santos, et al.
American Journal of Hematology|June 11, 2013
Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilizationVeronica R Smith, Uday Popat, Stefan Ciurea, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2013
Hematopoietic cell transplantation-specific comorbidity index predicts inpatient mortality and survival in patients who received allogeneic transplantation admitted to the intensive care unitUlas D Bayraktar, Elizabeth J Shpall, Ping Liu, et al.
Cancer|July 31, 2010
Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding studyMarcos de Lima, Sergio Giralt, Peter F Thall, et al.
Pageof 33